Eli Lilly (LLY) said it “has no affiliation with Mangoceuticals. Any communication or media report suggesting a partnership between Lilly and Mangoceuticals is false. In fact, Lilly sued Mangoceuticals last year and obtained a permanent injunction. While Lilly has no affiliation or partnership with Mangoceuticals, any healthcare provider-including those who work with telehealth platforms-can prescribe Lilly medicines and send valid, on-label prescriptions for Zepbound (tirzepatide) single-dose vials directly to LillyDirect Self Pay Pharmacy Solutions for fulfillment.” This follows Mangoceuticals (MGRX) announcement that it had launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound from Eli Lilly and Wegovy from Novo Nordisk (NVO). Shares of Mangoceuticals are sliding more than 16% in afternoon trading.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition
- Eli Lilly Stock Gets New Street-High Price Target – Citi Says Oral Weight-Loss Drug Sales Potential Is Underestimated
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls